Back to Search
Start Over
New antibodies recognizing p73: Comparison with commercial antibodies
- Source :
- Biochemical and Biophysical Research Communications. 330:186-193
- Publication Year :
- 2005
- Publisher :
- Elsevier BV, 2005.
-
Abstract
- p73, unlike p53, is expressed as a number of isomeric forms. Alternative splicing at the 3' end of p73 transcript, together with the usage of a second promoter downstream of exon 3, can generate up to 24 p73 isoforms. Variants lacking the TA domain (DeltaN isoforms) are induced by TAp73 and by p53, and inhibit their transcriptional activity. However, understanding the complex biology of p73 has been handicapped by the lack of high affinity specific antibodies for the different isoforms. Here, we report the characterization, by Western blotting and immunoprecipitation, of three new polyclonal antisera recognizing all p73 isoforms, only DeltaN isoforms or only p73alpha, and which have advantages of affinity and specificity over previously available antibodies.
- Subjects :
- Gene isoform
Immunoprecipitation
Blotting, Western
Biophysics
Biochemistry
Antibodies
Cell Line
Exon
Humans
Genes, Tumor Suppressor
skin and connective tissue diseases
neoplasms
Molecular Biology
Antiserum
biology
Immune Sera
Tumor Suppressor Proteins
Alternative splicing
Nuclear Proteins
Tumor Protein p73
Cell Biology
Molecular biology
DNA-Binding Proteins
Blot
Polyclonal antibodies
biology.protein
Antibody
Subjects
Details
- ISSN :
- 0006291X
- Volume :
- 330
- Database :
- OpenAIRE
- Journal :
- Biochemical and Biophysical Research Communications
- Accession number :
- edsair.doi.dedup.....89bfb8713527e976ece9ddc18360444f
- Full Text :
- https://doi.org/10.1016/j.bbrc.2005.02.145